Where Sarepta Therapeutics Stands With Analysts
Portfolio Pulse from Benzinga Insights
In the last quarter, Sarepta Therapeutics (NASDAQ:SRPT) received mostly bullish ratings from analysts, with an average 12-month price target of $179.04, up 3.64% from the previous average. The company has seen no bearish ratings in the past three months.
July 14, 2023 | 5:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sarepta Therapeutics has received mostly bullish ratings from analysts, indicating a positive outlook for the company's stock in the short term.
The bullish ratings from analysts indicate a positive sentiment towards Sarepta Therapeutics' stock. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100